Financial reports
10-K
2023 FY
Annual report
12 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
ARS
2022 FY
Annual report to shareholders
13 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
29 Mar 22
Current reports
8-K
CORMEDIX INC. REPORTS fourth QUARTER and full year 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
12 Mar 24
8-K
CORMEDIX INC. announces commercial AND REiMBURSEMENT updates
30 Jan 24
8-K
Departure of Directors or Certain Officers
15 Dec 23
8-K
CORMEDIX INC. ANNOUNCES FDA APProval of Defencath® To reduce
16 Nov 23
8-K
Cormedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
14 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
30 Oct 23
8-K
Departure of Directors or Certain Officers
17 Aug 23
8-K
CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2023 Financial Results and Provides Business Update
8 Aug 23
8-K
Cormedix Inc. Announces Proposed Public Offering of Common Stock and Pre-funded Warrants
30 Jun 23
8-K
Cormedix Inc. Announces Fda Acceptance of Resubmission of New Drug Application for Defencath
21 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
30 Jun 23
424B5
Prospectus supplement for primary offering
28 Jun 23
S-8
Registration of securities for employees
26 Oct 22
424B5
Prospectus supplement for primary offering
12 Aug 21
S-3
Shelf registration
12 Aug 21
424B5
Prospectus supplement for primary offering
5 Feb 21
8-A12B
Registration of securities on exchange
2 Feb 21
25
Voluntary exchange delisting
1 Feb 21
424B5
Prospectus supplement for primary offering
27 Nov 20
S-3
Shelf registration
6 Nov 20
Proxies
DEFA14A
Additional proxy soliciting materials
13 Sep 23
DEF 14A
Definitive proxy
13 Sep 23
DEFA14A
Additional proxy soliciting materials
30 Aug 22
DEF 14A
Definitive proxy
30 Aug 22
DEFA14A
Additional proxy soliciting materials
29 Oct 21
DEF 14A
Definitive proxy
29 Oct 21
DEF 14A
Definitive proxy
4 Nov 20
DEF 14A
Definitive proxy
17 Oct 19
DEFA14A
Additional proxy soliciting materials
17 Oct 19
DEFA14A
Additional proxy soliciting materials
1 Nov 18
Other
EFFECT
Notice of effectiveness
23 Aug 21
CORRESP
Correspondence with SEC
18 Aug 21
UPLOAD
Letter from SEC
18 Aug 21
CERT
Certification of approval for exchange listing
2 Feb 21
EFFECT
Notice of effectiveness
27 Nov 20
CORRESP
Correspondence with SEC
23 Nov 20
UPLOAD
Letter from SEC
12 Nov 20
CT ORDER
Confidential treatment order
26 Dec 19
EFFECT
Notice of effectiveness
24 Oct 18
UPLOAD
Letter from SEC
23 Oct 18
Ownership
4
Steven W Lefkowitz
20 Mar 24
4
Robert A Stewart
20 Mar 24
4
Myron Kaplan
20 Mar 24
4
Janet Dillione
20 Mar 24
4
ALAN W DUNTON
20 Mar 24
4
Gregory Scott Duncan
20 Mar 24
4
Joseph Todisco
14 Mar 24
SC 13G/A
NOMURA HOLDINGS INC
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24